AdaptImmune Accelerated Approval of First Approved Engineered Cell Therapy for Solid Tumor

 Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy

TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade

Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT

https://www.businesswire.com/news/home/20240801538240/en